Dr. Jaffer said it was “remarkable that even in a low-risk population, the prevalence of a CTO in CAD patients was 6%.” The discovery of a CTO “should prompt clinicians to evaluate the patient limit on excertional symptoms, both angina and dyspnea, and motivate the initiation of aggressive secondary prevention therapies,” he added.
Dr. Jaffer said it was “remarkable that even in a low-risk population, the prevalence of a CTO in CAD patients was 6%.” The discovery of a CTO “should prompt clinicians to evaluate the patient for limiting exertional symptoms, both angina and dyspnea, and motivate the initiation of aggressive secondary prevention therapies,” he added.